LinkedIn

 آمار

تعداد نشریات21
تعداد شماره‌ها1,292
تعداد مقالات11,793
تعداد مشاهده مقاله83,088,539
تعداد دریافت فایل اصل مقاله121,854,281
Najib, Fatemesadat, Shiravani, Zahra, Khoshdel, Maryam, Aghdaki, Maryam. (1405). Post-Neoadjuvant Chemotherapy Cancer Antigen-125 Levels and their association with Progression-Free and Overall Survival in Advanced‑Stage Epithelial Ovarian Cancer. سامانه مدیریت نشریات علمی, (), -. doi: 10.30476/mejc.2026.106949.2277
Fatemesadat Najib; Zahra Shiravani; Maryam Khoshdel; Maryam Aghdaki. "Post-Neoadjuvant Chemotherapy Cancer Antigen-125 Levels and their association with Progression-Free and Overall Survival in Advanced‑Stage Epithelial Ovarian Cancer". سامانه مدیریت نشریات علمی, , , 1405, -. doi: 10.30476/mejc.2026.106949.2277
Najib, Fatemesadat, Shiravani, Zahra, Khoshdel, Maryam, Aghdaki, Maryam. (1405). 'Post-Neoadjuvant Chemotherapy Cancer Antigen-125 Levels and their association with Progression-Free and Overall Survival in Advanced‑Stage Epithelial Ovarian Cancer', سامانه مدیریت نشریات علمی, (), pp. -. doi: 10.30476/mejc.2026.106949.2277
Najib, Fatemesadat, Shiravani, Zahra, Khoshdel, Maryam, Aghdaki, Maryam. Post-Neoadjuvant Chemotherapy Cancer Antigen-125 Levels and their association with Progression-Free and Overall Survival in Advanced‑Stage Epithelial Ovarian Cancer. سامانه مدیریت نشریات علمی, 1405; (): -. doi: 10.30476/mejc.2026.106949.2277

Post-Neoadjuvant Chemotherapy Cancer Antigen-125 Levels and their association with Progression-Free and Overall Survival in Advanced‑Stage Epithelial Ovarian Cancer

Middle East Journal of Cancer
مقالات آماده انتشار، پذیرفته شده، انتشار آنلاین از تاریخ 11 دی 1405    اصل مقاله (810.6 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/mejc.2026.106949.2277
نویسندگان
Fatemesadat Najib1؛ Zahra Shiravani* 1؛ Maryam Khoshdel2؛ Maryam Aghdaki1
1Department of Obstetrics and Gynecology, Shiraz University of Medical Sciences, Shiraz, Iran
2School, of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: In epithelial ovarian cancer (EOC), frequently diagnosed at an advanced stage, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery is a standard approach. Cancer antigen-125 (CA-125) is the cornerstone biomarker for monitoring treatment response, yet the prognostic value of its post-NACT levels and dynamic change relative to survival outcomes remains incompletely defined, particularly regarding optimal cutoffs for risk stratification in real-world clinical practice. This study aimed to investigate whether post-NACT CA-125 levels and their percentage reduction from baseline are independently associated with progression-free survival (PFS) and overall survival (OS) in patients with advanced (FIGO stage III–IV) EOC.
Methods: We performed a retrospective analysis of a synthetic cohort of 100 patients, modeled on real-world data. Pre- and post-NACT CA-125 levels were evaluated using Pearson correlation, Kaplan-Meier survival analysis, and multivariate Cox regression. Patients were stratified by post-treatment CA-125 (<50 vs. ≥50 U/mL) and percentage reduction (≥80% vs. <80%).
Results: Post-NACT CA-125 <50 U/mL (n = 42) was correlated with significantly longer PFS (median: 18.2 vs. 9.5 months; (hazard ratio) HR = 0.52, P = 0.002) and OS (48.3 vs. 32.1 months; HR = 0.61, P = 0.008). Similarly, ≥80% reduction (n = 58) was associated with improved PFS (16.7 vs. 10.4 months, P = 0.003) and OS (45.1 vs. 36.8 months, P = 0.015).
Conclusion: Post-NACT CA-125 levels and their dynamic reduction are robust prognostic biomarkers for survival in advanced EOC, supporting their integration into therapeutic follow-up for enhanced risk stratification. Prospective validation in real-world cohorts is warranted.

تازه های تحقیق

Zahra Shiravani (google scholar)

کلیدواژه‌ها
Epithelial ovarian cancer؛ Peritoneal cancer index؛ Overall survival؛ Progression-free survival؛ CA-125 antigen
مراجع
  1. Clancy E. ACS Report Shows Prostate Cancer on the Rise, Cervical Cancer on the Decline. [Internet] Renal & Urology News. 2023.[cited 2023, February 23]. Available at: https://www.renalandurologynews.com/news/acs-report-prostate-cancer-on-rise-cervical-cancer-on-decline/
  2. Zheng P, Zheng P, Chen G. Conditional survival of advanced epithelial ovarian cancer: A real-world data retrospective cohort study from the SEER database. Front Med (Lausanne). 2021;8:756401. doi: 10.3389/fmed.2021.756401. PMID: 34888325; PMCID: PMC8650058.
  3. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25):2403-15. doi: 10.1056/NEJMoa1909707. PMID: 31562800; PMCID: PMC6941439.
  4. Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019;29(4):728-60. doi: 10.1136/ijgc-2019-000308. PMID: 31048403.
  5. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. PMID: 26002111.
  6. Osborn G, Stavraka C, Adams R, Sayasneh A, Ghosh S, Montes A, et al. Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies. Clin Exp Immunol. 2022;209(1):4-21. doi: 10.1093/cei/uxab020. PMID: 35020853; PMCID: PMC9307234.
  7. Riedinger JM, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau JP, et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol. 2006;17(8):1234-8. doi: 10.1093/annonc/mdl120. PMID: 16766592.
  8. Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, et al. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2016;34(32):3854-63. doi: 10.1200/JCO.2016.68.1239. PMID: 27601552; PMCID: PMC5477982.
  9. Tanner EJ, Garg K, Leitao MM Jr, Soslow RA, Hensley ML. High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol. 2012;127(1):27-31. doi: 10.1016/j.ygyno.2012.06.030. PMID: 22750260.
  10. Merlo S, Besic N, Drmota E, Kovacevic N. Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer. Radiol Oncol. 2021;55(3):341-6. doi: 10.2478/raon-2021-0013. PMID: 33675192; PMCID: PMC8366730.
  11. Michielsen K, Vergote I, Op de Beeck K, Amant F, Leunen K, Moerman P, et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol. 2014;24(4):889-901. doi: 10.1007/s00330-013-3083-8. PMID: 24322510.
  12. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009;361(2):170-7. doi: 10.1056/NEJMcp0901926. PMID: 19587342.
  13. Kordowitzki P, Lange B, Elias KM, Haigis MC, Mechsner S, Braicu IE, et al. Transforming treatment paradigms: Focus on personalized medicine for high-grade serous ovarian cancer. CA Cancer J Clin. 2025;75(5):436-60. doi: 10.3322/caac.70008. PMID: 40252048; PMCID: PMC12432820.
  14. Chan JK, Tian C, Kesterson JP, Richardson MT, Lin K, Tewari KS, et al. The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study. Gynecol Oncol. 2022;167(3):429-35. doi: 10.1016/j.ygyno.2022.09.028. PMID: 36244828.
  15. Paramasivam S, Tripcony L, Crandon A, Quinn M, Hammond I, Marsden D, et al. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol. 2005;23(25):5938-42. doi: 10.1200/JCO.2005.08.151. PMID: 16087942.
  16. Fallon EA, Awiwi MO, Bhutiani N, Helmink B, Scally CP, Mansfield P, et al. Peritoneal cancer index correlates with radiographic assessment of colorectal carcinomatosis. Ann Surg Oncol. 2025;32:2923-31. doi: 10.1245/s10434-024-16737-0. PMID: 39730964; PMCID: PMC12244292.
  17. Llueca A, Climent MT, Escrig J, Carrasco P, Serra A. Validation of three predictive models for suboptimal cytoreductive surgery in advanced ovarian cancer. Sci Rep. 2021;11:8111. doi: 10.1038/s41598-021-86928-2. PMID: 33854085; PMCID: PMC8047030.
  18. Ngo TV, Dao LT, Tran AD, Le CT, Nguyen HX, Phung HT. Prognostic value of CT-PCI and CA-125 changes following neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A retrospective study from Vietnam. Gynecol Oncol Rep. 2025;61:101927. doi: 10.1016/j.gore.2025.101927. PMID: 41169956; PMCID: PMC12570090.
  19. Perrone AM, Coada CA, Ravegnini G, De Leo A, Damiano G, De Crescenzo E, et al. Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer. 2023;33(8):1270-8. doi: 10.1136/ijgc-2022-004249. PMID: 37429642; PMCID: PMC10423511.
آمار
تعداد مشاهده مقاله: 1
تعداد دریافت فایل اصل مقاله: 2


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب